A new European vaccine?
While several countries, such as France, are starting a booster campaign and injecting a third dose of vaccine into certain populations, the Franco-Austrian laboratory Valneva announced on Monday that it had started the gradual submission of its authorization request for its vaccine candidate. against Covid-19 with the British health authorities.
The laboratory's phase 3 trials, intended to prove the real effectiveness of a treatment before it is eventually put on the market, are still ongoing.
He hopes "that an initial authorization could be granted to it by the end of 2021" for marketing.
Valneva has already signed a contract with the United Kingdom to deliver this vaccine in the event of a positive test.
A "deactivated virus" vaccine
The first part of the phase 3 trials is taking place in the United Kingdom, but Valneva began in early August "a complementary trial" in New Zealand, with people over 56 years.
The laboratory uses a deactivated virus vaccine, a technology more traditional than those of vaccines currently approved in the European Union: Pfizer-BioNTech and Moderna, which are messenger RNA, and AstraZeneca and Johnson & Johnson, which work by viral vector.
Read alsoCovid-19: RNA, adenovirus, preservatives ... what exactly is in a dose of vaccine?
Recently, it was another European country, Spain, which announced advances in the vaccine it is developing.
The Spanish Medicines Agency approved in early August the launch of clinical trials on humans of the first Spanish vaccine against Covid-19.
Sanofi's French vaccine could be marketed at the end of 2021.